Biotech & Medtech
Biotech & Medtech news — Tuesday 06 October 2026
26 stories from 4 sources, every one in English. Each links to its publisher.
-
Opinion: Infectious disease expert: The mysterious pneumonia in Russia deserves attention, not panic
STAT News
Welcome to the debut of ID Consult, a new STAT column from infectious disease physician Krutika Kuppalli about diseases, outbreak response, global health, and health policy. A 28-year-old laboratory worker in Siberia develops severe…
-
Cybersecurity Experts to Hospital Leaders: Think Beyond Traditional Disaster-Recovery Planning
MedCity News
Cybersecurity leaders discussed how AI-driven cybersecurity attacks pose a new level of risk for hospitals and health systems at Rubrik’s Healthcare Summit last week. The post Cybersecurity Experts to Hospital Leaders: Think Beyond…
-
FTC Sends Warning Letters to 24 Healthcare Organizations Over Price Transparency
MedCity News
The FTC sent warning letters to 24 major healthcare organizations over concerns about inadequate price transparency. The post FTC Sends Warning Letters to 24 Healthcare Organizations Over Price Transparency appeared first on MedCity News .
-
Forbion Bucks VC Fundraising Trends, Reeling In €2.3B for Two New Funds
MedCity News
Forbion’s new capital will support two funds that will invest in about 30 companies combined. The new funds for Netherlands-based Forbion come amid a decline in VC fundraising and investments in Europe, according to Pitchbook. The post…
-
Forbion, a prominent biotech investor, raises $2.6B for a pair of venture funds
BioPharma Dive
The fundraise is the firm’s largest to date, providing a lift for a European biotech industry that’s fallen further behind its counterparts in the U.S. and China.
-
ArriVent collapses on disappointing lung cancer data
BioPharma Dive
More than half of the company’s value was wiped out by findings that appear to erase a chance to battle Johnson & Johnson and others for market share.
-
Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial
BioPharma Dive
The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.
-
STAT+: AstraZeneca opens new Boston site
STAT News
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. From DC to Boston to Utah, we’ve got news from all over today. The need-to-know this morning…
-
STAT+: Are stem cell treatments about to have their day?
STAT News
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Celebrity doctor Mike Varshavski has…
-
What are hospital longevity programs, and what can they tell you about your health?
STAT News
For patients willing to pay thousands of dollars out of pocket, prestigious hospitals across the country are offering a new speciality: longevity. Cash-pay longevity clinics promise to monitor all sorts of health indicators and provide…
-
STAT+: FDA spells out 2027 AI guidance plans
STAT News
Y ou’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Good morning health tech readers! Just…
-
STAT+: Pharmalittle: We’re reading about U.S.-funded psychedelic trials, an AstraZeneca R＆D center, and more
STAT News
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and comfy breezes are greeting us. As for the official mascots, they are happily…
-
Perimenopause Anxiety: Sometimes It’s a Progesterone Deficiency
MedCity News
Perimenopausal anxiety isn’t simply in our patients’ heads. It’s often the result of complex physiologic changes involving hormones, sleep, metabolism, and the nervous system. The post Perimenopause Anxiety: Sometimes It’s a Progesterone…
-
MedTech VC 2026: The Real Story vs. The Thesis
MedCity News
I kept hearing “medtech VC is in decline,” so I decided to dig into the data myself. I expected shrinking investor interest, inflated valuations, and a weak exit environment. Instead, I found a more nuanced story. The post MedTech VC 2026…
-
The top biopharma conferences in 2027
BioPharma Dive
Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch for in 2027.
-
Deciding when to get your flu shot? Consider these factors
STAT News
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here . Today’s newsletter answers some pressing questions — what is optogenetics? When should I get my flu shot, as cases rise in…
-
Hidden Risks and Costs of Maternal/Infant Health that Health Plans Miss
MedCity News
[Sponsored] A new report from ProgenyHealth offers a window into how the business works with commercial and Medicaid plans to close gaps in maternity and NICU care management that traditional programs overlook. The post Hidden Risks and…
-
GE HealthCare to acquire Sofie Biosciences for $945M
BioPharma Dive
The purchase expands GE HealthCare’s radiopharmaceutical capabilities, helping manufacture and distribute time-sensitive drugs used in PET imaging.
-
Opinion: I’m a doctor. Here’s what I want the public to know about AI tools and health care costs
STAT News
When Blue Cross Blue Shield recently published research suggesting that hospitals use artificial intelligence tools to extract more money from insurers without providing additional care, people were mad . Amid growing concerns about AI…
-
In this hospital, pulse oximeters went from overestimating to underestimating blood oxygen. Why?
STAT News
Pulse oximeters gained prominence during the Covid-19 pandemic, offering anyone a handheld tool to take stock of their blood oxygen level. But their newfound popularity also brought new attention to their limitations — several studies have…
-
STAT+: Can you live longer for $5,500? Longevity clinics are the buzzy new trend at nonprofit hospitals
STAT News
CHICAGO — I was walking briskly on a steep treadmill, wearing a mask that evoked the villain Bane from “Batman.” Prince crooned back-handed compliments over an iPad speaker to keep my energy up, promising I had to be neither rich nor cool…
-
Opinion: Why the FDA should not approve an ineffective multicancer screening test
STAT News
There must be some mistake. A company studies its cancer blood test in a randomized trial of 140,000 people using a suboptimal surrogate endpoint, fails to meet that endpoint, yet is recommended for approval by a Food and Drug…
-
Shotgun engineering fires up mammalian metabolic design
Nature Biotechnology
Nature Biotechnology, Published online: 06 October 2026; doi:10.1038/s41587-026-03329-4 By testing random combinations of genes at scale, shotgun genetic engineering enables discovery of new productive metabolic pathways in mammalian…
-
Highly multiplexed mammalian metabolic engineering with a shotgun approach
Nature Biotechnology
Nature Biotechnology, Published online: 06 October 2026; doi:10.1038/s41587-026-03318-7 Metabolic engineering of mammalian cells is simplified and scaled by screening ‘shotgun’ modifications.
-
High-throughput metabolic engineering in mammalian cells
Nature Biotechnology
Nature Biotechnology, Published online: 06 October 2026; doi:10.1038/s41587-026-03317-8 Engineering complex phenotypes into mammalian cells holds profound potential but remains a largely intractable engineering challenge. We developed…
-
Decoding systemic vascular health and hypertensive disorders in pregnancy through retinal imaging and Visionary AI
Nature Biotechnology
Nature Biotechnology, Published online: 06 October 2026; doi:10.1038/s41587-026-03303-0 An interpretable artificial intelligence framework predicts hypertensive disorders of pregnancy using retinal images and vascular modeling.